DiscoveryBioMed, Inc. Engaged in Multiple Drug Discovery Projects on Behalf of Mount Sinai School of Medicine and It’s Office of Technology and Business Development

*DiscoveryBioMed’s Human Cell Cultures and Novel Methods Being Used to Launch Multiple Drug Discovery Projects to Discover New Therapeutics for Human Disease*

BIRMINGHAM, AL and New York, NY – DiscoveryBioMed, Inc. and Mount Sinai School of Medicine (MSSM) have agreed to move forward on multiple “fee for service” contracts in human cell optimization, assay optimization and pilot drug discovery bioassays on behalf of the Mount Sinai Office of Technology and Business Development (OTBD) and MSSM investigators.

"DiscoveryBioMed is very pleased that MSSM has chosen our company and its novel approaches to the drug discovery process to begin work on these initial projects” said DBM’s CEO Dr. Erik Schwiebert. “We seek to provide access to drug discovery infrastructure at a reasonable cost to academic clients. We also see our academic clients as partners in the process." Experiments have already commenced on assay optimization and pilot drug screening will begin shortly. DiscoveryBioMed has developed several commercial-academic partnerships over its first 15 months of formal operation. DBM’s particular expertise is the development and/or engineering of human cell cultures and lines from normal or diseased tissue that serve as relevant platforms on which to accelerate this drug discovery process. It is the early formative steps of a drug discovery program that are critical, even before the first small molecule is screened. “As part of this joint effort, DBM is using a particular human cell model that is especially relevant to one of these projects and is building assays around other relevant human cell lines that will serve as the drug discovery platforms” explained Dr. Eric Seales, Chief Laboratory Officer. CEO Dr. Erik Schwiebert explains DBM’s novel core principle in a simple way: “One is going to eventually treat a human with the best discovered lead compounds going forward so why not screen on a human cell background.”

"We are pleased to have a partner in DBM who provides us with drug discovery services consistent with our academic needs and capabilities” Patrick McGrath, Executive Director of MSSM’s OTBD said. “We have been expanding our resources and capabilities in the area of technology development in order to further typical academic early stage technologies to a point that they are more attractive to partners who can translate the technology into products and service that can benefit the public.” “We anticipate that our partnership with DBM will help us meet this goal by identifying lead compounds against new disease relevant pathways some of which will hopefully lead to new therapeutics”. “In the absence of these technology development resources academic technologies often are not further developed in a commercial direction and as a result potentially useful products and services go unexplored”

**About DiscoveryBioMed, Inc.**

DiscoveryBioMed, Inc. is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and drug discovery. The company is located within Innovation Depot in Birmingham. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, it focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its “fee-for-service” support to researchers in allied areas and currently serves
clients both locally in Alabama as well as in 10 other states in the US currently. For more information, visit the DBM website at www.discoverybiomed.com.

About Mount Sinai School of Medicine and the Office of Technology and Business Development
MSSM is internationally recognized as a leader in groundbreaking clinical and basic-science research, as well as having an innovative approach to medical education. With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, MSSM ranks among the top 20 medical schools in receipt of National Institute of Health (NIH) grants.

MSSM’s OTBD is the intellectual property commercialization arm of MSSM. The mission of OTBD is to foster a culture of innovation and to facilitate the development and commercialization of MSSM intellectual property and translation of MSSM research into products and services, in ways that are consistent with the public good and traditional concerns for academic freedom and independence. One of the focuses of the OTBD is to develop early stage technologies to a stage that they can overcome commercially relevant barriers and thus be more attractive to potential commercial partners. As part of this focus, OTBD is seeking partnerships with drug discovery companies to identify lead compounds to biologic targets identified at MSSM but which may not be pursued in the absence of a technology development program. For more information visit MSSM’s OTBD website at www.mssm.edu/otbd.

CONTACTS:

DBM Contact: Erik Schwiebert, Ph.D.
Phone: 205-307-6535 x 1
Email: erik@discoverybiomed.com

MSSM OTBD Contact:
Eric Vieira, Ph.D.
Phone: 212-659-9680
Email: eric.vieira@mssm.edu